Relapsed or Refractory T-cell Lymphomas
Oncology·MeSH: Lymphoma
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 4(1)
| Drug | Company |
|---|---|
| bms-986369 | BRISTOL MYERS SQUIBB CO (BMY) |
Frequently asked questions
How many drugs are in development for Relapsed or Refractory T-cell Lymphomas?
BioSniper tracks 1 drug in development for Relapsed or Refractory T-cell Lymphomas across 1 company.
How many clinical trials target Relapsed or Refractory T-cell Lymphomas?
There are 1 clinical trial targeting Relapsed or Refractory T-cell Lymphomas tracked by BioSniper.
Deep-dive into Relapsed or Refractory T-cell Lymphomas
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis